| Literature DB >> 33649255 |
Hye Jeong Park1, Dai Hoon Han1, Gi Hong Choi1, Jin Sub Choi1.
Abstract
BACKGROUNDS/AIMS: Although it is difficult to master the surgical learning curve for treatment of perihilar cholangiocarcinoma (HCCA), there have been no studies on surgical outcomes between a novice and an experienced surgeon. Thus, the current study attempted to evaluate surgical outcomes from a single surgeon based on learning curve for surgical treatment of HCCA.Entities:
Keywords: Learning curve; Perihilar cholangiocarcinoma; Surgical outcome
Year: 2021 PMID: 33649255 PMCID: PMC7952677 DOI: 10.14701/ahbps.2021.25.1.54
Source DB: PubMed Journal: Ann Hepatobiliary Pancreat Surg ISSN: 2508-5859
Fig. 1Flow diagram of study design. For the study, 101 of 108 consecutive patients who underwent surgical treatment for HCCA were selected. Of these, 73 patients with one-side liver resection without vascular resection were selected to evaluate the learning curve. The 27th of 73 selected patients was the first test patient after stabilization of the learning curve. This 27th patient was matched to the 43rd consecutive of 101 patients. Thus, the study group was subdivided into the early period group (n=42) and the late period group (n=59).
Fig. 2CUSUM and moving average graph by operation time for evaluating the learning curve. (A) CUSUM with operation time for 73 consecutive patients with hemi-hepatectomy or trisectionectomy without vascular resection. A CUSUM=0 meant the operation time was the same as the mean operation time. A positive CUSUM meant the operation time was shorter than the mean operation time. The operation times were steadily shorter than the mean operation time after the 27th case. (B) Moving average graph for each of five serial cases. A logistic regression graph was drawn to identify the learning achievement point. The steep slope of the logistic regression graph before the 27th case started to flatten after the 27th case. Thus, the learning curve may be stabilized after the 27th of 73 consecutive patients.
Fig. 3Early versus late period group assignment according to case-matching. The 27th of 73 patients with a one-side hepatectomy without vascular resection (b, green bar) was matched to the 43rd of 101 consecutive patients. The first 42 patients were classified as the early period group, and the subsequent 59 patients were classified as the late period group.
Patient characteristics
| Variables | EPG (n=42) | LPG (n=59) | |
|---|---|---|---|
| Sex (male:female) | 24:18 | 41:18 | 0.202 |
| Age | 62.29±10.59 | 66.00±9.99 | 0.075 |
| Pre-OP laboratory findings | |||
| Albumin (g/dl) | 3.53±0.44 | 3.55±0.45 | 0.845 |
| AST (IU/L) | 42.36±28.37 | 39.97±23.20 | 0.643 |
| ALT (IU/L) | 35.79±25.81 | 45.44±40.64 | 0.178 |
| GGT (IU/L) | 445.98±453.69 | 344.15±291.17 | 0.205 |
| CEA (ng/ml) | 4.13±5.87 | 3.82±5.66 | 0.969 |
| CA 19-9 (U/ml) | 1166.77±3339.59 | 468.03±1071.22 | 0.197 |
| Total bilirubin (mg/dl) | 1.69±1.08 | 1.36±0.79 | 0.099 |
| Highest total bilirubin (mg/dl) | 8.33±6.30 | 6.87±6.53 | 0.266 |
| Neoadjuvant CCRT | 6 (14.3%) | 26 (44.1%) | 0.002 |
| PVE | 3 (7.1%) | 14 (23.7%) | 0.028 |
| Bismuth-Corlette type | |||
| I | 3 (7.1%) | 2 (3.4%) | |
| II | 8 (19.0%) | 8 (13.6%) | |
| IIIa | 8 (19.0%) | 26 (44.1%) | |
| IIIb | 4 (9.5%) | 9 (15.3%) | |
| IV | 19 (45.2%) | 14 (23.7%) | |
| AJCC stage | |||
| 0 | 1 (2.4%) | 2 (3.4%) | |
| I | 1 (2.4%) | 2 (3.4%) | |
| II | 20 (47.6%) | 28 (47.5%) | |
| IIIA | 0 (0%) | 7 (11.9%) | |
| IIIB | 18 (42.9%) | 17 (28.8%) | |
| IVB | 2 (4.8%) | 3 (5.1%) |
EPG, early period group; LPG, late period group; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; CCRT, concurrent chemo-radiation therapy; PVE, portal vein embolization; AJCC, American Joint Committee on Cancer; LN, lymph node
Perioperative outcomes
| Variables | EPG (n=42) | LPG (n=59) | |
|---|---|---|---|
| Liver resection type | |||
| Rt. hemihepatectomy | 11 (26.2%) | 30 (50.8%) | |
| Lt. hemihepatectomy | 13 (31.0%) | 19 (32.2%) | |
| Rt. trisectionectomy | 1 (2.4%) | 3 (5.1%) | |
| Lt. trisectionectomy | 8 (19.0%) | 0 (0%) | |
| Caudate lobectomy | 0 (0%) | 1 (1.7%) | |
| Central bisectionectomy | 2 (4.8%) | 5 (8.5%) | |
| Anterior sectionectomy | 1 (2.4%) | 1 (1.7%) | |
| Segmentectomy 4 | 6 (14.3%) | 0 (0%) | |
| LN metastasis | 21 (50.0%) | 19 (32.2%) | 0.071 |
| R0 resection | 36 (85.7%) | 45 (76.3%) | 0.241 |
| LN retrieval ≥4 | 39 (92.9%) | 52 (88.1%) | 0.434 |
| Operation time (minutes) | 603.17±117.59 | 432.03±91.77 | <0.001 |
| Bleeding amount during operation (ml) | 1127.86±689.54 | 613.05±548.31 | <0.001 |
| Length of hospital stay (day) | 23 (16-30) | 18 (12.25-23) | 0.025 |
| Overall complications | 31 (73.8%) | 38 (64.4%) | 0.317 |
| Severe complications | 20 (47.6%) | 16 (27.1%) | 0.034 |
| Perioperative mortality | 3 (7.1%) | 1 (1.7%) | 0.166 |
EPG, early period group; LPG, late period group; Rt., right; Lt., left; LN, lymph node
Fig. 4Comparison Overall survival and Disease free survival graph between two groups. (A) The 5-year overall survival rate was 21.6% and 37.8% in the EPG and LPG, respectively (p=0.412). (B) The 5-year disease free survival rate was 28.5% and 30.2% for the EPG and LPG, respectively (p=0.642).
Disease-free survival and overall survival with multivariate analysis
| Variables | Coefficient | Standard error | Relative risk (95% CI) | |
|---|---|---|---|---|
| Disease-free survival | ||||
| Pre-OP CEA | 0.895 | 0.308 | 0.004 | 2.139-2.755 |
| LN metastasis | 0.502 | 0.254 | 0.048 | 1.398-1.906 |
| Overall survival | ||||
| Pre-op serum albumin | 0.741 | 0.258 | 0.004 | 1.840-2.356 |
| Pre-OP CEA | 0.668 | 0.322 | 0.038 | 1.629-2.273 |
LN, lymph node; Pre-op, preoperative; CEA, carcinoembryonic antigen